Aldeyra Therapeutics, Inc.
ALDX
$4.88
$0.010.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 49.13% | 42.03% | -22.86% | -232.61% | -84.60% |
| Total Depreciation and Amortization | 1.11% | 1.14% | 0.50% | -3.16% | -3.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.16% | -112.60% | 31.11% | 215.41% | 211.21% |
| Change in Net Operating Assets | -140.77% | -36.97% | -40.27% | -51.57% | 648.12% |
| Cash from Operations | 11.96% | 35.31% | -25.04% | -2,505.44% | 0.62% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 375.05% | 96.96% | 124.00% | -- | -- |
| Cash from Investing | 375.05% | 96.96% | 124.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 71.94% | -- |
| Issuance of Common Stock | 506.53% | -- | 5,409.89% | 1,059.93% | -90.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 161.14% | -- | 5,409.89% | 100.77% | 37.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 722.03% | 71.05% | 89.64% | -2,555.38% | 65.11% |